OncoMatch/Endometrial / Uterine Cancer/MMR / MSI-H
Endometrial / Uterine CancerMMR / MSI-H Clinical Trials
Mismatch repair deficiency (dMMR) defines approximately 25–30% of endometrial cancers, primarily endometrioid histology, and is the most actionable biomarker in this disease. Dostarlimab and pembrolizumab are both FDA-approved as monotherapy for dMMR advanced endometrial cancer; pembrolizumab plus lenvatinib is approved regardless of MMR status. Trials explore neoadjuvant immunotherapy, CTLA-4/LAG-3 combinations, and IO-based strategies that could replace chemotherapy in dMMR endometrial cancer.
Top recruiting MMR / MSI-H Endometrial / Uterine Cancer trials
Ranked by phase and US site count. See all 8 trials matched to your profile →
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
AstraZeneca
Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer
Gustave Roussy, Cancer Campus, Grand Paris
Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features
Leiden University Medical Center
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Memorial Sloan Kettering Cancer Center
Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
University Medical Center Groningen
TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC
Fudan University
Browse other molecular targets with active Endometrial / Uterine Cancer trials.